Clinical Trial Search

Primary: Number of Participants With at Least One Positive SARS-CoV-2 Antibody Test. — 563 Participants

Primary: Immunoglobulins (G and M) to SARS-Cov2 in Plasma — 4.86; 65.32; 64.17 Titres

Primary: Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] — 4; 1; 19 Participants

Primary: Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml — -3.16; -3.31; -3.26; -3.20 log10 HIV-1 RNA — p=0.26

Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 113; 0; 7; 6 participants

Primary: Left Ventricular Mass Index — 67; 60 g/m2 — p=0.27

Primary: Quality of Life/Well-being (Young People) — 4.77 score on a scale

Primary: Safety of Treatment With High-titer Anti-SARS-CoV-2 Plasma as Assessed by Adverse Events — 0 Participants

Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…

Primary: Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV — 1; 4; 0; 0 participants

Primary: Difference in CD4+ T Cell Percentage Between Week 0 and Week 48 — -10.08 percentage of CD4+ T cells — p=<0.0001

Primary: Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk. — 1.32; 2.25 Episodes/ Person-Yr at Risk — p=0.04

Primary: Number of Participants With Viral Suppression — 289; 283 participants — p=0.55

Primary: Area Under the Plasma Concentration Time Curve (AUC) From 0-12 Hours for Enfuvirtide and Its Metabolite (Ro 50-6343) — 56.1; 52.7; 3.07; 3.41 microgram hour per…

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD — 14.4; 5.5; 15.9; 7.1 Percent change from baseline — p=<0.001

Primary: Grade 3 or Higher Adverse Events Through 24 Weeks — 13; 10 Participants — p=0.40

Primary: Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV in the First 21 Days After Vaccine Administration Days in…

Primary: Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1) — 23840.1 hr*ng/mL

Primary: Viral Rebound — 0.284; 0.176 probability of viral rebound — p=<0.001

Primary: Non-fasting Cholesterol — 187.2; 178.5; 181.5 mg/dL — p=.006

Primary: Cohorts 1 and 2: Pharmacokinetics (PK) of Rilpivirine (TMC278) as Measured by Maximum Observed Plasma Concentration at Steady State (Cmax,ss) — 109; 154; 238 nanograms…

Primary: Area Under the Plasma Concentration-time Curve From Time of Administration up to 24 Hours Postdose (AUC[0-24h]) of Rilpivirine 12.5 mg (for <20 kg Group) — 4116; 4646…

Primary: Geometric Mean Area Under the Plasma Concentration-time Curve Over 24 Hours (AUC0-24h) for ABC, DTG, and 3TC — 17.7; 19.8; 15.1; 17.4 h*ug/mL

Primary: AUC0-42day in 3-dose Study — 4.47; 14.9; 49.7; 14.6 hr.ug/mL

Primary: Pharmacokinetic (PK) Parameter (Cohort 1): AUCtau of Tenofovir Alafenamide (TAF) — 139.9; 200.6 h*ng/mL

Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440

Primary: For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG — 31620.9 ng•h/mL

Primary: Effectiveness of SEARCH Youth Intervention — 88.2; 80.5; 90.9; 85.3 % of participants — p=0.0019

Primary: Pharmacokinetic (PK) Parameter: Single-dose Area-under-the-curve (AUC0-∞) of Doravirine (DOR) (Cohort 1) — 34.8 µM*hr